Jason Hafron, MD, presents the profile of a 66-year-old man with metastatic castration-sensitive prostate cancer (mCSPC).
The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy
March 27th 2023"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.
Study evaluates polygenic risk score for prostate cancer risk prediction
March 18th 2023“Vanderbilt researchers are participating in numerous projects related to PRS and disease risk; studies such as this highlight the importance of evaluating whether novel clinical tools actually enhance care,” said Kerry Schaffer, MD.
2 Clarke Drive
Cranbury, NJ 08512